Talk:Huperzine A

From PsychonautWiki
Jump to navigation Jump to search


This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: Huperzine A
Huperzine A
Chemical Nomenclature
Common names DMT, Dimethyltryptamine, Dmitri
Substitutive name N,N-Dimethyltryptamine
Systematic name 2-(1H-Indol-3-yl)-N,N-dimethylethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Bioavailability x% - y%[1]
Threshold x - mg
Light x - y mg
Common x - y mg
Strong x - y mg
Heavy x mg +
Total x - y hours
Onset x - y minutes
Come up x - y minutes
Peak x - y hours
Offset x - y hours
After effects x - y hours

Bioavailability x% - y%
Threshold x - mg
Light x - y mg
Common x - y mg
Strong x - y mg
Heavy x mg +
Total a - b hours
Onset a - b minutes
Come up a - b minutes
Peak a - b hours
Offset a - b hours
After effects a - b hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


For tips on how to properly format a substance article, please refer to this document: Content Style Guide - Substance

Huperzine A is a drug used to treat alzheimers and schizophrenia induced cognitive impairment. It is also used as a nootropic. It is a natural compound that occurs in multiple plants in the genus Huperzia and was first isolated and pharmacologically characterized by Chinese scientists in 1986 [2].

History and culture

History icon.svg

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

Since initial discovery, scientists have been interested in huperzine A due to its pharmacological profile and potential anti-neurodegenerative properties [3]. Huperzine A has indeed been shown to indirectly influence several signaling pathways associated with neuroprotection, including neurotrophic factors or Wnt, and decreased amyloid beta accumulation in vivo.[4]. Besides its popularity in biomedical research, huperzine A is also commonly sold as a supplement for its ability to improve cognitive function. However, some placebo controled studies indicate low efficiancy [5].

Among psychonauts, huperzine A has also found its popularity as a dream potentiator and inducer of lucid dreams, similar to the less available galantamine [6]



This chemistry section is incomplete.

You can help by adding to it.

Huperzine A is a polycyclic sesquiterpene alkaloid with molecular formula of C15H18N2O [7]. Its biosynthesis is not well researched and likely involves both precursors of isoprenoids and alkaloids [8]. Multiple total syntheses have also been performed [9].


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Huperzine A acts as a powerful acetylcholinesterase inhibitor as well as an NMDA antagonist.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

It is strongly recommended that one use harm reduction practices when using this substance.

Lethal dosage

Tolerance and addiction potential

Dangerous interactions


This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

See also

External links


  • APA formatted reference

Please see the citation formatting guide if you need assistance properly formatting citations.


  1. APA formatted citation.
  2. Wang YE, Yue DX, Tang XC. [Anti-cholinesterase activity of huperzine A]. Zhongguo Yao Li Xue Bao. 1986 Mar;7(2):110-3. Chinese. PMID: 2946143.
  3. Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013 Sep 23;8(9):e74916. doi: 10.1371/journal.pone.0074916. PMID: 24086396; PMCID: PMC3781107.
  4. Friedli MJ, Inestrosa NC. Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease. Molecules. 2021 Oct 29;26(21):6531. doi: 10.3390/molecules26216531. PMID: 34770940; PMCID: PMC8587556.
  5. Wessinger CM, Inman CL, Weinstock J, Weiss EP. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial. Int J Exerc Sci. 2021 Aug 1;14(2):727-741. PMID: 34567353; PMCID: PMC8439683.
  7. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 854026, Huperzine A. Retrieved November 21, 2023 from
  8. Li X, Li W, Tian P, Tan T. Delineating biosynthesis of Huperzine A, A plant-derived medicine for the treatment of Alzheimer's disease. Biotechnol Adv. 2022 Nov;60:108026. doi: 10.1016/j.biotechadv.2022.108026. Epub 2022 Jul 30. PMID: 35914626.
  9. Total Synthesis of (−)-Huperzine A Takahiro Koshiba, Satoshi Yokoshima, and Tohru Fukuyama Organic Letters 2009 11 (22), 5354-5356 DOI: 10.1021/ol9022408